Shanghai Pharmaceuticals Holding Co., Ltd (HKG:2607)
Hong Kong
· Delayed Price · Currency is HKD 11.86
+0.04 (0.34%)
Jul 4, 2025, 4:08 PM HKT
HKG:2607 Revenue
Shanghai Pharmaceuticals Holding had revenue of 70.76B CNY in the quarter ending March 31, 2025, with 0.87% growth. This brings the company's revenue in the last twelve months to 275.86B, up 4.41% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B with 5.75% growth.
Revenue (ttm)
275.86B CNY
Revenue Growth
+4.41%
P/S Ratio
0.22
Revenue / Employee
5.58M CNY
Employees
49,402
Market Cap
65.70B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.25B | 14.96B | 5.75% |
| Dec 31, 2023 | 260.30B | 28.31B | 12.21% |
| Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
| Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
| Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |
Shanghai Pharmaceuticals Holding News
- 6 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 6 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha